Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial

Sinead Delany-Moretlwe*, Carl Lombard, Deborah Baron, Linda Gail Bekker, Busi Nkala, Khatija Ahmed, Modulakgotla Sebe, William Brumskine, Maposhane Nchabeleng, Thesla Palanee-Philips, Julius Ntshangase, Sidney Sibiya, Emilee Smith, Ravindre Panchia, Landon Myer, Jill L. Schwartz, Mark Marzinke, Lynn Morris, Elizabeth R. Brown, Gustavo F. DoncelGlenda Gray, Helen Rees

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

63 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial'. Together they form a unique fingerprint.

Medicine & Life Sciences